Receptor News and Research

RSS

Single receptor PAR1 controls opposing responses in blood vessels

Researchers at the University of California San Diego have uncovered how a single protein triggers two opposite responses in blood vessels - one inflammatory and one protective.

10 Mar 2026

Protein aggregates in the liver may protect against alcohol-induced damage

Alcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and liver-related mortality worldwide, with few effective therapies.

9 Mar 2026

$Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia$

Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T cells to target specific antigens on leukemia cells, with the goal of identifying and eliminating them.

9 Mar 2026

Taking anticoagulants alongside prostate cancer drugs does not increase bleeding risk

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients' bleeding or clotting risks, despite previous lab results that raised alarms.

9 Mar 2026

Most weight lost on GLP-1 drugs returns within a year after stopping

The cessation of GLP-1RAs is linked to a 60% weight regain within a year, emphasizing the importance of tailored strategies for effective long-term weight loss.

9 Mar 2026

New peptide fragments teach the gut to tolerate food

In little moments like when sipping coffee or licking an ice cream cone, it doesn't seem like your body is pulling off a biological miracle. But it is. That cookie is not you-yet when you put it in your mouth, your body is able to tolerate it and process it without any detriment to your health in a process called oral tolerance. How does the human body make that decision between tolerance and rejection?

9 Mar 2026

Could GLP-1 drugs help curb addiction? Large veteran study points to potential benefit

A large cohort study of more than 600,000 US veterans with type 2 diabetes found that initiating GLP-1 receptor agonists was associated with lower risks of developing substance use disorders compared with SGLT-2 inhibitors. Among veterans with existing substance use disorders, GLP-1 receptor agonist use was also linked to fewer overdose events, hospitalizations, and suicide-related outcomes.

8 Mar 2026

Med14 protein drives GLP-1 benefits in pancreatic beta cells

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve cardiovascular health.

6 Mar 2026

Modified psilocybin compounds may treat brain disorders with fewer hallucinations

Psilocybin - the psychoactive compound in "magic mushrooms" - is gaining scientific attention for its potential in treating neuropsychiatric conditions including depression, anxiety, substance use disorders and certain neurodegenerative diseases.

6 Mar 2026

NIH grant supports research on immune-related receptor in neurons

Florida Atlantic University has received a $2.4 million grant from the National Institutes of Health to investigate how an immune-related receptor in neurons plays a fundamental role in brain function, behavior and psychiatric health.

6 Mar 2026

PET imaging reveals molecular mechanism behind ketamine's antidepressant effects

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond adequately to conventional antidepressant therapies.

6 Mar 2026

Engineered lettuce may turn injectable GLP-1 therapies into oral pills

Few drugs have entered mainstream awareness as quickly or as dramatically as glucagon-like peptide-1, or GLP-1 receptor agonists. Initially approved by the FDA for the treatment of type 2 diabetes, they have since also transformed the therapeutic landscape of obesity and weight management.

6 Mar 2026

Single dose of CAR-astrocyte therapy halves amyloid levels in mice brains

The new generation of Alzheimer's disease drugs - the first proven to change the course of the disease - typically extend independent living for patients by 10 months.

6 Mar 2026

New compound shows promise in protecting the liver from damage after small bowel surgery

When parts of the small intestine are diseased or die, the treatment can involve surgically removing the affected tissue.

6 Mar 2026

A review of methionine dependency in modern cancer therapy

Methionine restriction (MR) has shown significant promise in cancer therapy because it targets the unique methionine dependency of many tumors. However, despite extensive research on MR, a clear synthesis of preclinical findings and their translation into clinical settings is lacking. This review aims to address this gap by consolidating existing evidence, identifying challenges, and highlighting opportunities for advancing MR as a viable cancer treatment strategy.

6 Mar 2026

Drug combination shows greater weight loss while preserving muscle mass

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue.

5 Mar 2026

Single injection may help the heart heal after heart attack

For people who have survived a heart attack, the notion of one shot in the arm to help the heart heal, for weeks after, may seem far‑fetched. But thanks to a team of researchers, including a Texas A&M University professor, that's exactly what could happen.

5 Mar 2026

Repurposed kidney drug finerenone shows promise in treating premature ovarian insufficiency

Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 to 3% of women of childbearing age.

5 Mar 2026

Long COVID taste loss tied to reduced expression of key taste genes

The study identifies molecular changes in taste receptor cells as a potential cause of persistent taste dysfunction in long COVID-19, impacting quality of life.

5 Mar 2026

Novel gene regulation therapy passes key clinical milestone

Groundbreaking Phase 1/2a clinical trials co-led by Linda Laux, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, show that the first gene regulation treatment for epilepsy is safe and well tolerated by patients with Dravet syndrome for whom antiseizure medications are not effective.

4 Mar 2026